PR Newswire Clinical TrialsOriginal article
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
Phase 3positiveSKYRIZIRINVOQPositive
AI Analysis
Summary
AbbVie announced positive Phase 3 AFFIRM data showing SKYRIZI (risankizumab-rzaa) demonstrated higher rates of clinical and endoscopic response versus placebo across all efficacy endpoints in Crohn's disease patients. Open-label extension analyses demonstrated sustained endoscopic outcomes for SKYRIZI and RINVOQ (upadacitinib) in inflammatory bowel disease.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups
Importance:7/10
Sentiment:
0.75
Phase 3 dataCrohn's diseaseinflammatory bowel diseaseclinical efficacyendoscopic responseopen-label extension
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 11, 2026 5:00 PM